News

The Experimental Drug Development Centre (EDDC), Singapore’s national platform for drug discovery and development hosted by the Agency for Science, Technology and Research (A*STAR) is collaborating with Sprint Bioscience, a Swedish biotech company focused on preclinical discovery and development of small molecule first-in-class programmes, with oncology as a key therapeutic area.     In this […]

EBC-129 is an antibody-drug conjugate (ADC) that selectively targets a novel, tumour-specific N-glycosylated epitope found on both CEACAM5 and CEACAM6. The expansion cohort for pancreatic ductal adenocarcinoma (PDAC) in the ongoing Phase 1 trial has completed enrolment. Notably, 82% of patients had tumours expressing the antigen at levels considered treatable with EBC-129.   EBC-129 demonstrated positive

EBC-129 is the first made-in-Singapore antibody-drug conjugate (ADC) to enter clinical development. It selectively targets a tumour-specific N-glycosylated epitope on both CEACAM5 and CEACAM6. The Fast Track Designation highlights the potential of EBC-129 to address critical unmet needs in pancreatic ductal adenocarcinoma (PDAC). Updated clinical data from the ongoing Phase 1 study of EBC-129 will

This marks the first-ever collaboration between Engine Biosciences and Experimental Drug Development Centre (EDDC), Singapore’s national platform for drug discovery and development. The partnership will advance the development of first-in-class precision therapeutics for multiple cancer types that are highly prevalent in Singapore and globally, including breast, liver, kidney and prostate cancers. Engine Biosciences (Engine), a

In September 2024, we showcased our phase 1 dose escalation study for EBC-129 (NCT05701527) at European Society for Medical Oncology (ESMO) Congress.   Further to the ESMO poster presentation, we are happy to announce that we have completed enrolment of the pancreatic ductal adenocarcinoma (PDAC) cohort in the ongoing dose expansion part of EBC-129’s Phase

EDDC is excited to share that we will be collaborating with Partex, a leading provider of AI-driven solutions in the pharmaceutical industry, to bring forward an innovative approach for early drug discovery and development. In this partnership, Partex will initially use its “Asset Exchange” technology platform to identify novel indications for EDDC’s portfolio assets. The parties

EBC-129 is the first made-in-Singapore antibody-drug conjugate (ADC) to enter clinical development. It selectively targets cancer cells across a range of solid tumours. The Phase 1 trial for EBC-129 began with a dose escalation study in May 2023. The trial has entered into dose expansion as of 13 May 2024. With the initial safety and

EDDC is proud to share that we are embarking on a partnership with ImmunoScape to develop novel T cell receptor-based therapeutics!  Under the terms of the agreement, ImmunoScape will contribute their repertoire of highly potent tumor-specific TCR candidates to EDDC’s expertise in therapeutic protein design and antibody engineering, to jointly develop innovative off-the-shelf TCR-based bispecific

XtalPi and EDDC embarks on a new collaboration with the signing of this MoU. This agreement builds and expands from an ongoing collaboration that utilizes AI and automation to accelerate the drug discovery program for non-small cell lung cancer (NSCLC). With XtalPi’s automation resources and AI capabilities complimenting EDDC’s industry know-how in drug discovery and

EARO turns 3 this year! To mark this occasion, we are excited to share the EARO Review (2020-2022)! EDDC launched EARO (the EDDC Academic Research Organisation) as a service initiative in mid-2020. The goal was to enable early-stage drug discovery in Singapore by creating multiple pathways for the local academic and biotech community to access